Kiora Pharmaceuticals
KPRX
16 hedge funds and large institutions have $19M invested in Kiora Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.
583,004% more capital inflows, than outflows
Capital inflows: $11.7M | Capital outflows: $2K
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
33% more funds holding
Funds holding: 12 → 16 (+4)
12.92% more ownership
Funds ownership: 40.8% → 53.72% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$9.27M |
| 2 |
Renaissance Technologies
New York
|
+$887K |
| 3 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$456K |
| 4 |
Two Sigma Advisers
New York
|
+$392K |
| 5 |
Two Sigma Investments
New York
|
+$320K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
-$2K |
KPRX Hedge Fund Activity: Q1 2021 in Review
16 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2021, worth a combined $19M — up 104% from $9.31M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KPRX positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, adding an estimated $9.27M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $2K sold.
- 16 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2021, up from 12 in Q4 2020.
- Funds reported $19M of Kiora Pharmaceuticals stock for Q1 2021, up 104% quarter-over-quarter.
- 6 funds opened new Kiora Pharmaceuticals positions in Q1 2021 and 1 closed out, a net change of +5 holders.
- The largest Kiora Pharmaceuticals buyer in Q1 2021 was Armistice Capital, an estimated $9.27M added.
- The largest Kiora Pharmaceuticals seller in Q1 2021 was Tower Research Capital (TRC), an estimated $2K sold.
Based on aggregated 13F filings for Q1 2021.